Upifitimab rilsodotin for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Apr 2022: Trial registered, NCT05329545
  2. 23 Jun 2022: Trial started, NCT05329545
  3. 29 Sep 2023: Trial terminated, NCT05329545

The trials

NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

State
Stopped early
Phase
Phase 3
People
20 taking part
Started
23 Jun 2022
Primary completion
29 Sep 2023
Arms
XMT-1536 (upifitamab rilsodotin)
Results
None posted
  1. 15 Apr 2022: Trial registered
  2. 23 Jun 2022: Trial started
  3. 29 Sep 2023: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.